Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 2/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | PPARG | P37231 | 1/20 | 0.44 |
| ▸ | PPARD | Q03181 | 1/20 | 0.44 |
| ▸ | PPARA | Q07869 | 1/20 | 0.44 |
| ▸ | ESR1 | P03372 | 1/20 | 0.44 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12807303 | 0.94 | GAA (0.51) | PTGS2SMN1; SMN2MAPTTP53GAA | |
| SCHEMBL1507666 | 0.94 | SMN1; SMN2 (0.54) | PTGS2SMN1; SMN2MAPTGAAALDH1A1 | |
| SCHEMBL197602 | 0.88 | PTGS2 (0.58) | PTGS2MAPTTP53GAAALDH1A1 | |
| SCHEMBL15426838 | 0.88 | MEN1 (0.53) | PTGS2SMN1; SMN2MAPTGAAALDH1A1 | |
| SCHEMBL14039512 | 0.85 | PTGS2 (0.47) | PTGS2SMN1; SMN2MAPTGAAALDH1A1 | |
| SCHEMBL1507830 | 0.85 | PTGS2 (0.47) | PTGS2SMN1; SMN2MAPTGAAALDH1A1 | |
| SCHEMBL14039419 | 0.85 | ALDH1A1 (0.47) | PTGS2SMN1; SMN2MAPTGAAALDH1A1 | |
| SCHEMBL1507597 | 0.84 | SMN1; SMN2 (0.70) | SMN1; SMN2ALDH1A1PPARDPPARAESR1 | |
| SCHEMBL7848337 | 0.83 | SMN1; SMN2 (0.69) | PTGS2SMN1; SMN2MAPTGAAALDH1A1 | |
| SCHEMBL12227872 | 0.83 | SMN1; SMN2 (0.54) | PTGS2SMN1; SMN2MAPTGAAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2305246-B1 | Tumor necrosis factor inhibitors | UNIV PENNSYLVANIA (US) | 2015-08-26 | — | — | EP | disclosed |
| EP-2305246-B1 | Tumor necrosis factor inhibitors | UNIV PENNSYLVANIA (US) | 2015-08-26 | — | — | EP | disclosed |
| US-9096607-B2 | Tumor necrosis factor inhibitors | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2015-08-04 | — | — | US | disclosed |
| US-9096607-B2 | Tumor necrosis factor inhibitors | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2015-08-04 | — | — | US | disclosed |
| US-9096607-B2 | Tumor necrosis factor inhibitors | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2015-08-04 | — | — | US | disclosed |
| US-20140256803-A1 | TUMOR NECROSIS FACTOR INHIBITORS | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2014-09-11 | — | — | US | disclosed |
| US-20140256803-A1 | TUMOR NECROSIS FACTOR INHIBITORS | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2014-09-11 | — | — | US | disclosed |
| US-20140256803-A1 | TUMOR NECROSIS FACTOR INHIBITORS | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2014-09-11 | — | — | US | disclosed |
| US-8765810-B2 | Tumor necrosis factor inhibitors | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2014-07-01 | — | — | US | disclosed |
| US-8765810-B2 | Tumor necrosis factor inhibitors | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2014-07-01 | — | — | US | disclosed |
| US-20130072562-A1 | TUMOR NECROSIS FACTOR INHIBITORS | CEPHALON, INC. (US) | 2013-03-21 | — | — | US | disclosed |
| US-8318699-B2 | Tumor necrosis factor inhibitors | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2012-11-27 | — | — | US | disclosed |
| US-8318699-B2 | Tumor necrosis factor inhibitors | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2012-11-27 | — | — | US | disclosed |
| US-8318699-B2 | Tumor necrosis factor inhibitors | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2012-11-27 | — | — | US | disclosed |
| EP-2305246-A1 | Tumor necrosis factor inhibitors | Ception Therapeutics, Inc. (US) | 2011-04-06 | — | — | EP | disclosed |
| EP-2298295-A1 | Tumor necrosis factor inhibitors | Ception Therapeutics, Inc. (US) | 2011-03-23 | — | — | EP | disclosed |
| EP-2298295-A1 | Tumor necrosis factor inhibitors | Ception Therapeutics, Inc. (US) | 2011-03-23 | — | — | EP | disclosed |
| US-20090221527-A1 | TUMOR NECROSIS FACTOR INHIBITORS | CEPTION THERAPEUTICS, INC. (US) | 2009-09-03 | — | — | US | disclosed |
| US-20090221527-A1 | TUMOR NECROSIS FACTOR INHIBITORS | CEPTION THERAPEUTICS, INC. (US) | 2009-09-03 | — | — | US | disclosed |
| US-20090221527-A1 | TUMOR NECROSIS FACTOR INHIBITORS | CEPTION THERAPEUTICS, INC. (US) | 2009-09-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090221527-A1 | TUMOR NECROSIS FACTOR INHIBITORS | TNFRSF1A, TNF, TNFRSF9 | PTGS2 280/4885SMN1; SMN2 4740/4885MAPT 3981/4885 |
| US-20140256803-A1 | TUMOR NECROSIS FACTOR INHIBITORS | TNFRSF1A, TNF, TNFRSF9 | PTGS2 280/4885SMN1; SMN2 4740/4885MAPT 3981/4885 |
| US-20130072562-A1 | TUMOR NECROSIS FACTOR INHIBITORS | TNFRSF1A, TNF, TNFRSF9 | PTGS2 280/4885SMN1; SMN2 4740/4885MAPT 3981/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.